Logo image of IQV

IQVIA HOLDINGS INC (IQV) Stock Fundamental Analysis

NYSE:IQV - New York Stock Exchange, Inc. - US46266C1053 - Common Stock - Currency: USD

144.95  +1.41 (+0.98%)

After market: 144.95 0 (0%)

Fundamental Rating

5

Overall IQV gets a fundamental rating of 5 out of 10. We evaluated IQV against 56 industry peers in the Life Sciences Tools & Services industry. While IQV has a great profitability rating, there are quite some concerns on its financial health. IQV scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

In the past year IQV was profitable.
IQV had a positive operating cash flow in the past year.
In the past 5 years IQV has always been profitable.
IQV had a positive operating cash flow in each of the past 5 years.
IQV Yearly Net Income VS EBIT VS OCF VS FCFIQV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B 2.5B

1.2 Ratios

Looking at the Return On Assets, with a value of 4.88%, IQV belongs to the top of the industry, outperforming 80.36% of the companies in the same industry.
The Return On Equity of IQV (22.32%) is better than 94.64% of its industry peers.
The Return On Invested Capital of IQV (9.88%) is better than 85.71% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IQV is below the industry average of 12.97%.
The 3 year average ROIC (8.99%) for IQV is below the current ROIC(9.88%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.88%
ROE 22.32%
ROIC 9.88%
ROA(3y)4.83%
ROA(5y)3.91%
ROE(3y)21.26%
ROE(5y)16.88%
ROIC(3y)8.99%
ROIC(5y)7.35%
IQV Yearly ROA, ROE, ROICIQV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 -40 -60

1.3 Margins

Looking at the Profit Margin, with a value of 8.61%, IQV is in the better half of the industry, outperforming 76.79% of the companies in the same industry.
IQV's Profit Margin has improved in the last couple of years.
IQV's Operating Margin of 14.67% is fine compared to the rest of the industry. IQV outperforms 78.57% of its industry peers.
IQV's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 34.72%, IQV is doing worse than 62.50% of the companies in the same industry.
IQV's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 14.67%
PM (TTM) 8.61%
GM 34.72%
OM growth 3Y13.09%
OM growth 5Y13.9%
PM growth 3Y8.58%
PM growth 5Y38.92%
GM growth 3Y1.42%
GM growth 5Y0.42%
IQV Yearly Profit, Operating, Gross MarginsIQV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), IQV is destroying value.
IQV has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, IQV has less shares outstanding
The debt/assets ratio for IQV is higher compared to a year ago.
IQV Yearly Shares OutstandingIQV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
IQV Yearly Total Debt VS Total AssetsIQV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.2 Solvency

IQV has an Altman-Z score of 1.83. This is not the best score and indicates that IQV is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of IQV (1.83) is comparable to the rest of the industry.
The Debt to FCF ratio of IQV is 6.63, which is on the high side as it means it would take IQV, 6.63 years of fcf income to pay off all of its debts.
IQV has a Debt to FCF ratio (6.63) which is in line with its industry peers.
A Debt/Equity ratio of 2.19 is on the high side and indicates that IQV has dependencies on debt financing.
IQV has a worse Debt to Equity ratio (2.19) than 82.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF 6.63
Altman-Z 1.83
ROIC/WACC0.99
WACC9.97%
IQV Yearly LT Debt VS Equity VS FCFIQV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2B 4B 6B 8B 10B

2.3 Liquidity

IQV has a Current Ratio of 0.82. This is a bad value and indicates that IQV is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.82, IQV is doing worse than 91.07% of the companies in the same industry.
IQV has a Quick Ratio of 0.82. This is a bad value and indicates that IQV is not financially healthy enough and could expect problems in meeting its short term obligations.
IQV has a worse Quick ratio (0.82) than 83.93% of its industry peers.
Industry RankSector Rank
Current Ratio 0.82
Quick Ratio 0.82
IQV Yearly Current Assets VS Current LiabilitesIQV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.71% over the past year.
Measured over the past years, IQV shows a quite strong growth in Earnings Per Share. The EPS has been growing by 11.72% on average per year.
The Revenue has been growing slightly by 2.84% in the past year.
Measured over the past years, IQV shows a small growth in Revenue. The Revenue has been growing by 6.80% on average per year.
EPS 1Y (TTM)9.71%
EPS 3Y7.25%
EPS 5Y11.72%
EPS Q2Q%6.3%
Revenue 1Y (TTM)2.84%
Revenue growth 3Y3.55%
Revenue growth 5Y6.8%
Sales Q2Q%2.46%

3.2 Future

The Earnings Per Share is expected to grow by 11.54% on average over the next years. This is quite good.
The Revenue is expected to grow by 5.94% on average over the next years.
EPS Next Y7.39%
EPS Next 2Y8.77%
EPS Next 3Y9.46%
EPS Next 5Y11.54%
Revenue Next Year4.54%
Revenue Next 2Y4.87%
Revenue Next 3Y5.12%
Revenue Next 5Y5.94%

3.3 Evolution

The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
IQV Yearly Revenue VS EstimatesIQV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B 20B 25B
IQV Yearly EPS VS EstimatesIQV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 5 10 15 20

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.83 indicates a correct valuation of IQV.
Based on the Price/Earnings ratio, IQV is valued cheaply inside the industry as 92.86% of the companies are valued more expensively.
Compared to an average S&P500 Price/Earnings ratio of 26.60, IQV is valued rather cheaply.
The Price/Forward Earnings ratio is 11.00, which indicates a very decent valuation of IQV.
94.64% of the companies in the same industry are more expensive than IQV, based on the Price/Forward Earnings ratio.
IQV is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.43, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 12.83
Fwd PE 11
IQV Price Earnings VS Forward Price EarningsIQV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

92.86% of the companies in the same industry are more expensive than IQV, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, IQV is valued cheaper than 96.43% of the companies in the same industry.
Industry RankSector Rank
P/FCF 11.82
EV/EBITDA 11.18
IQV Per share dataIQV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 50 -50

4.3 Compensation for Growth

IQV's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
The decent profitability rating of IQV may justify a higher PE ratio.
PEG (NY)1.74
PEG (5Y)1.09
EPS Next 2Y8.77%
EPS Next 3Y9.46%

More info and screens

0

5. Dividend

5.1 Amount

IQV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IQVIA HOLDINGS INC

NYSE:IQV (5/20/2025, 8:06:12 PM)

After market: 144.95 0 (0%)

144.95

+1.41 (+0.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-06 2025-05-06/bmo
Earnings (Next)07-21 2025-07-21/bmo
Inst Owners96.4%
Inst Owner Change0.64%
Ins Owners0.94%
Ins Owner Change1.32%
Market Cap25.56B
Analysts80
Price Target219.17 (51.2%)
Short Float %1.61%
Short Ratio1.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.47%
Min EPS beat(2)-0.62%
Max EPS beat(2)1.56%
EPS beat(4)3
Avg EPS beat(4)0.72%
Min EPS beat(4)-0.62%
Max EPS beat(4)1.9%
EPS beat(8)6
Avg EPS beat(8)0.79%
EPS beat(12)9
Avg EPS beat(12)0.92%
EPS beat(16)13
Avg EPS beat(16)1.17%
Revenue beat(2)1
Avg Revenue beat(2)0.05%
Min Revenue beat(2)-0.4%
Max Revenue beat(2)0.5%
Revenue beat(4)1
Avg Revenue beat(4)-0.06%
Min Revenue beat(4)-0.4%
Max Revenue beat(4)0.5%
Revenue beat(8)2
Avg Revenue beat(8)-0.25%
Revenue beat(12)4
Avg Revenue beat(12)-0.19%
Revenue beat(16)7
Avg Revenue beat(16)0.11%
PT rev (1m)-11.94%
PT rev (3m)-13.43%
EPS NQ rev (1m)-2.13%
EPS NQ rev (3m)-2.17%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)-0.29%
Revenue NQ rev (1m)1.32%
Revenue NQ rev (3m)1.04%
Revenue NY rev (1m)1.21%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE 12.83
Fwd PE 11
P/S 1.65
P/FCF 11.82
P/OCF 9.25
P/B 4.28
P/tB N/A
EV/EBITDA 11.18
EPS(TTM)11.3
EY7.8%
EPS(NY)13.18
Fwd EY9.09%
FCF(TTM)12.27
FCFY8.46%
OCF(TTM)15.66
OCFY10.81%
SpS87.89
BVpS33.9
TBVpS-76.87
PEG (NY)1.74
PEG (5Y)1.09
Profitability
Industry RankSector Rank
ROA 4.88%
ROE 22.32%
ROCE 11.28%
ROIC 9.88%
ROICexc 10.89%
ROICexgc N/A
OM 14.67%
PM (TTM) 8.61%
GM 34.72%
FCFM 13.96%
ROA(3y)4.83%
ROA(5y)3.91%
ROE(3y)21.26%
ROE(5y)16.88%
ROIC(3y)8.99%
ROIC(5y)7.35%
ROICexc(3y)9.76%
ROICexc(5y)7.99%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)10.28%
ROCE(5y)8.4%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3Y16.83%
ROICexc growth 5Y22.05%
OM growth 3Y13.09%
OM growth 5Y13.9%
PM growth 3Y8.58%
PM growth 5Y38.92%
GM growth 3Y1.42%
GM growth 5Y0.42%
F-Score6
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 2.19
Debt/FCF 6.63
Debt/EBITDA 3.87
Cap/Depr 53.72%
Cap/Sales 3.87%
Interest Coverage 250
Cash Conversion 81.52%
Profit Quality 162.14%
Current Ratio 0.82
Quick Ratio 0.82
Altman-Z 1.83
F-Score6
WACC9.97%
ROIC/WACC0.99
Cap/Depr(3y)57.12%
Cap/Depr(5y)53.97%
Cap/Sales(3y)4.31%
Cap/Sales(5y)4.59%
Profit Quality(3y)136.6%
Profit Quality(5y)225.89%
High Growth Momentum
Growth
EPS 1Y (TTM)9.71%
EPS 3Y7.25%
EPS 5Y11.72%
EPS Q2Q%6.3%
EPS Next Y7.39%
EPS Next 2Y8.77%
EPS Next 3Y9.46%
EPS Next 5Y11.54%
Revenue 1Y (TTM)2.84%
Revenue growth 3Y3.55%
Revenue growth 5Y6.8%
Sales Q2Q%2.46%
Revenue Next Year4.54%
Revenue Next 2Y4.87%
Revenue Next 3Y5.12%
Revenue Next 5Y5.94%
EBIT growth 1Y8.55%
EBIT growth 3Y17.1%
EBIT growth 5Y21.64%
EBIT Next Year22.55%
EBIT Next 3Y12.06%
EBIT Next 5Y10.62%
FCF growth 1Y43.44%
FCF growth 3Y-2.8%
FCF growth 5Y20.42%
OCF growth 1Y27.34%
OCF growth 3Y-2.63%
OCF growth 5Y13.9%